Clinical Trial Update: Safety and Efficacy of Inhaled Treprostinil in Patients With PAH [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating inhaled treprostinil for pulmonary arterial hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Tyvaso (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: WITHDRAWN